Abstract
BackgroundTo assess the feasibility of validating microRNA (miRNA) profile related to paclitaxel-sensitivity in formalin-fixed paraffin-embedded (FFPE) samples of serous ovarian carcinoma (OC) patients.MethodsDeregulated miRNAs identified by miRNA microarray were further detected in 45 FFPE OC samples using Realtime PCR. Correlations between paired FFPE and frozen tumor samples were analyzed. Survival times were compared between 6 high and low miRNAs groups. Western blot and luciferase reporter assay were used for validating the target of miRNA.ResultsSixteen up-regulated miRNAs and twenty-three down-regulated miRNAs were revealed in pacilitaxel-resistant ST30 cells. The up-regulated miRNAs (miR-320a, 22 and 129-5p) and down-regulated miRNAs (miR-9, 155 and 640) were confirmed in paclitaxel-resistant FFPE tumor samples, compared with paclitaxel-sensitive samples. Higher miR-9 and miR-640 showed better survival time in OC patients. Expressions of miR-9, 155 and 22 in FFPE samples were closely mimicked by those in frozen tissues. RAB34 was validated as a direct target of miR-9.ConclusionsWe validated miRNA profile in pacilitaxel-resistant OC using FFPE samples, which might enable treatment stratification and help us to predict outcomes in OC patients. FFPE samples are feasible materials for miRNA research.
Highlights
To assess the feasibility of validating microRNA profile related to paclitaxel-sensitivity in formalin-fixed paraffin-embedded (FFPE) samples of serous ovarian carcinoma (OC) patients
Confirmed paclitaxel-resistant miRNA profile using FFPE samples The miRNA microarray revealed that 39 miRNAs showed more than 1.5 fold deregulation between the pacilitaxel resistant and sensitive cell lines (Figure 1A)
To determine the significance of these miRNAs, realtime PCR was performed using 45 FFPE ovarian carcinoma samples. miR-320a, 22 and 129-5p were significantly up-regulated in FFPE paclitaxel-resistant tumor samples (P=0.019, 0.025, 0.007), while miR-9, 155 and 640 were significantly down-regulated (P=0.009, 0.027 and 0.001 respectively) (Figure 1B), compared with paclitaxel-sensitive samples
Summary
To assess the feasibility of validating microRNA (miRNA) profile related to paclitaxel-sensitivity in formalin-fixed paraffin-embedded (FFPE) samples of serous ovarian carcinoma (OC) patients. Ovarian carcinoma (OC) is the leading cause of death among patients with gynecologic cancer. Drug resistance remains a formidable problem in managing cancer patients. MicroRNA (miRNA)s are small noncoding RNAs involved in the initiation and progression of human cancer [3]. As modulators of protein expression they may cell lines, when we detected the miRNAs expressions using miRNA microarray in present study. This raises the question that whether a miRNA profile representing paclitaxel-resistance could be useful for prognosticating clinical chemo-resistance in OC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
